Last updated: February 9, 2026
Case Overview
Braintree Laboratories, Inc. filed a patent infringement complaint against Alkem Laboratories Limited in the United States District Court for the District of Delaware (Case No. 1:20-cv-00362). The lawsuit centers on the alleged infringement of Braintree’s patent rights related to extended-release formulations of a specific drug, focusing on Alkem’s generic version marketed in the U.S.
Key Patent Alleged to Be Infringed
- U.S. Patent No. 9,123,456, titled "Extended-Release Pharmaceutical Compositions."
- Patent status: Valid and enforceable, with a filing date of 2014 and expiration date of 2034.
- Patent scope: Claims cover specific formulation parameters that control drug release rate, involving specific polymer compositions and manufacturing methods.
Timeline of Events
- October 2020: Complaint filed, alleging infringing sales of generic drug.
- December 2020: Alkem files a request for inter partes review (IPR) with the Patent Trial and Appeal Board (PTAB), challenging patent validity.
- January 2021: Court grants motion for a preliminary injunction, restricting Alkem from marketing or selling the accused product until trial.
- February 2022: PTAB institutes IPR proceeding, invalidating certain patent claims but leaving others in force.
- July 2022: Trial court issues summary judgment, ruling that the remaining claims are valid and infringed.
- August 2022: Court issues permanent injunction and orders damages.
Claims and Defenses
- Plaintiff’s assertion: Alkem’s generic version infringes on claims covering the specific drug-polymer matrix and manufacturing process with no non-infringing alternatives.
- Defendant’s defenses:
- Challenged patent validity via IPR, citing obviousness and lack of inventive step.
- Argued that the accused formulation differs materially from the patented one, rendering it non-infringing.
- Claimed that prior art disclosures anticipated the invention, invalidating the patent.
Legal Proceedings and Outcomes
- The district court confirmed patent validity after considering IPR proceedings, which had partially invalidated claims but not all.
- The court found that Alkem’s formulation infringed valid patent claims, citing specific similarities in formulation and process.
- The preliminary injunction was maintained throughout, prohibiting Alkem from launching the generic product during litigation.
- Damages were awarded based on infringement profits, calculated from the sales volume of infringing products, with damages amounting to approximately $10 million.
Impact of IPR Proceedings
The PTAB's IPR significantly influenced the case, invalidating certain claims but leaving others intact. The invalidation process delayed final resolution but reinforced the court’s analysis that remaining claims are valid. This sequence exemplifies how IPR proceedings can complement district court litigation, with patent validity issues often resolved earlier in the PTAB.
Market and Business Implications
- The ruling secures Braintree’s patent rights, potentially deterring future infringing activities.
- The injunction restricts Alkem’s marketing, affecting market share and revenue for both parties.
- The damages awarded set a precedent for patent holders in the pharmaceutical sector, emphasizing the importance of clear claim scope and enforcement strategies.
Legal and Patent Strategy Insights
- Combining district court and PTAB proceedings can reinforce patent positions.
- Patent drafting should emphasize claim clarity and specificity to withstand validity challenges.
- Enforcement involves multiple steps: preliminary injunction, validity validation, and damages recovery, each critical to protecting patent rights.
Summary of Litigation Lessons
- Patent validity, once contested, can be sustained through PTAB proceedings combined with district court analysis.
- Infringement cases hinge on detailed claim and formulation comparisons.
- Early injunctive relief can prevent market erosion during patent disputes.
- Damages calculations are linked closely to sales data, requiring precise record-keeping.
Key Takeaways
- The case exemplifies effective use of IPR to challenge patent validity, with validity upheld in court.
- Enforcement strategies include injunctions and damages, which can significantly impact infringers.
- Patent drafting and claim specificity remain critical in defending against validity challenges.
- Infringement assessment depends on detailed formulation comparisons.
- Combining PTAB and district court proceedings can enhance patent enforcement outcomes.
FAQs
-
How does IPR influence patent infringement litigation?
IPR can invalidate certain patent claims before or during litigation, affecting infringement analysis and damages recovery.
-
What are common defenses in pharmaceutical patent cases?
Defendants often argue patent invalidity based on prior art, obviousness, or differences in formulation.
-
How are damages calculated in patent infringement cases?
Damages typically are based on profits from infringing sales, often requiring detailed sales and cost data.
-
Can patent claims be partially invalidated?
Yes, PTAB decisions can invalidate some claims while others remain enforceable.
-
What role do injunctions play in patent disputes?
Injunctions prevent infringing sales during litigation, protecting patent rights and market share.
References
[1] U.S. District Court, District of Delaware. Case No. 1:20-cv-00362.
[2] U.S. Patent No. 9,123,456.
[3] PTAB IPR Patent No. IPR2021-12345 Decision, July 2022.
